About us Contacts Drug interactions: 390 212
Drug search by name

Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate and Darolutamide

Determining the interaction of Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate and Darolutamide and the possibility of their joint administration.

Check result:
Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate <> Darolutamide
Relevance: 12.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir. According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported. MANAGEMENT: The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided. If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended. Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Professional:

GENERALLY AVOID: Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir. According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.

MANAGEMENT: The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided. If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended. Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate

Generic Name: bictegravir / emtricitabine / tenofovir alafenamide

Brand name: Biktarvy

Synonyms: Bictegravir, emtricitabine, and tenofovir, Emtricitabine, and Tenofovir Alafenamide

Darolutamide

Generic Name: darolutamide

Brand name: Nubeqa

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.